Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

Tutt, Andrew; E. Garber, Judy; Kaufman, Bella; Viale, Giuseppe; Fumagalli, Debora; Rastogi, Priya; D. Gelber, Richard; de Azambuja, Evandro; Fielding, Anitra; Balmaña, Judith; M. Domchek, Susan; A. Gelmon, Karen; J. Hollingsworth, Simon; A. Korde, Larissa; Linderholm, Barbro; Bandos, Hanna; Senkus, Elżbieta; M. Suga, Jennifer; Shao, Zhimin; W. Pippas, Andrew; Nowecki, Zbigniew; Huzarski, Tomasz; A. Ganz, Patricia; C. Lucas, Peter; Baker, Nigel; Loibl, Sibylle; McConnell, Robin; Piccart, Martine; K. Schmutzler, Rita; G. Steger, Guenther; P. Costantino, Joseph; Arahmani, Amal; Wolmark, Norman; McFadden, Eleanor; Karantza, Vassiliki; R. Lakhani, Sunil; Yothers, Greg; Campbell, Christine; E. Geyer, Charles

doi:10.1056/nejmoa2105215

Public

Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

Published in New England Journal of Medicine • Jun 3, 2021

Authors:

Andrew Tutt

Judy E. Garber

Bella Kaufman

Abstract

BACKGROUND: germline mutation-associated early breast cancer. METHODS: germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors who had received local treatment and neoadjuvant or adjuvant chemotherapy. Patients were randomly assigned (in a 1:1 ratio) to 1 year of ...

Subject

Olaparib

Synthetic lethality

Breast cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!